Patient preferences for intervention in the setting of precursor multiple myeloma.
作者信息
Marinac Catherine R, Downey Katelyn, Perry Jacqueline, Fisher-Longden Brittany, Rebbeck Timothy R, Shah Urvi A, O'Donnell Elizabeth K, Ghobrial Irene M, Nadeem Omar, Egleston Brian L
机构信息
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, US.
Centers for Early Detection and Interception, Dana-Farber Cancer Institute, Boston, MA, US.
出版信息
Blood Cancer J. 2024 Oct 14;14(1):175. doi: 10.1038/s41408-024-01161-0.
Abstract
摘要
相似文献
1
Patient preferences for intervention in the setting of precursor multiple myeloma.前驱多发性骨髓瘤患者对干预措施的偏好
Blood Cancer J. 2024 Oct 14;14(1):175. doi: 10.1038/s41408-024-01161-0.
2
Individual Trade-Offs Between Possible Benefits and Risks of Cancer Treatments: Results from a Stated Preference Study with Patients with Multiple Myeloma.癌症治疗的可能获益与风险的个体权衡：来自多发性骨髓瘤患者的意愿性研究结果。
Oncologist. 2018 Jan;23(1):44-51. doi: 10.1634/theoncologist.2017-0257. Epub 2017 Oct 27.
3
Alignment of preferences in the treatment of multiple myeloma - a discrete choice experiment of patient, carer, physician, and nurse preferences.多发性骨髓瘤治疗偏好的一致性 - 基于患者、照顾者、医生和护士偏好的离散选择实验。
BMC Cancer. 2020 Jun 11;20(1):546. doi: 10.1186/s12885-020-07018-6.
4
Older adults newly diagnosed with symptomatic myeloma and treatment decision making.新诊断出有症状骨髓瘤的老年人及治疗决策
Oncol Nurs Forum. 2014 Jul 1;41(4):411-9. doi: 10.1188/14.ONF.411-419.
5
Physical Activity Preferences for People Living With Multiple Myeloma: A Qualitative Study.多发性骨髓瘤患者的身体活动偏好：一项定性研究。
Cancer Nurs. 2017 Sep/Oct;40(5):E1-E8. doi: 10.1097/NCC.0000000000000425.
6
Understanding health outcome preferences of older adults diagnosed with multiple myeloma.了解诊断为多发性骨髓瘤的老年患者的健康结局偏好。
J Geriatr Oncol. 2024 Jun;15(5):101781. doi: 10.1016/j.jgo.2024.101781. Epub 2024 May 6.
7
The EASEMENT study: A multicentre, observational, cross-sectional study to evaluate patient preferences, treatment satisfaction, quality of life, and healthcare resource use in patients with multiple myeloma receiving injectable-containing or fully oral therapies.EASEMENT 研究：一项多中心、观察性、横断面研究，旨在评估接受含注射剂或全口服治疗的多发性骨髓瘤患者的患者偏好、治疗满意度、生活质量和医疗资源利用情况。
Eur J Haematol. 2024 Jun;112(6):889-899. doi: 10.1111/ejh.14180. Epub 2024 Feb 23.
8
Analysis of physicians' perspectives versus patients' preferences: direct assessment and discrete choice experiments in the therapy of multiple myeloma.分析医生观点与患者偏好：多发性骨髓瘤治疗中的直接评估和离散选择实验。
Eur J Health Econ. 2011 Jun;12(3):193-203. doi: 10.1007/s10198-010-0218-6. Epub 2010 Jan 28.
9
MMpowerment: Empowering patients with multiple myeloma for shared decision-making by developing an intervention to integrate personal preferences into digital care pathways.MMpowerment：通过开发一种将个人偏好整合到数字护理路径中的干预措施，赋予多发性骨髓瘤患者共同决策的能力。
Z Evid Fortbild Qual Gesundhwes. 2024 Jun;187:53-60. doi: 10.1016/j.zefq.2024.04.002. Epub 2024 May 23.
10
Psychosocial support in patients with multiple myeloma at time of diagnosis: who wants what?多发性骨髓瘤患者确诊时的心理社会支持：患者需要什么？
Psychooncology. 2013 Oct;22(10):2313-20. doi: 10.1002/pon.3284. Epub 2013 Apr 11.
本文引用的文献
1
Patient Preferences for Multi-Cancer Early Detection (MCED) Screening Tests.患者对多癌种早期检测（MCED）筛查测试的偏好。
Patient. 2023 Jan;16(1):43-56. doi: 10.1007/s40271-022-00589-5. Epub 2022 Jul 18.
2
How I approach smoldering multiple myeloma.我是如何处理冒烟型多发性骨髓瘤的。
Blood. 2022 Aug 25;140(8):828-838. doi: 10.1182/blood.2021011670.
3
Carfilzomib, Lenalidomide, and Dexamethasone Followed by Lenalidomide Maintenance for Prevention of Symptomatic Multiple Myeloma in Patients With High-risk Smoldering Myeloma: A Phase 2 Nonrandomized Controlled Trial.卡非佐米、来那度胺和地塞米松治疗后序贯来那度胺维持治疗高危冒烟型骨髓瘤患者预防症状性多发性骨髓瘤的Ⅱ期非随机对照试验
JAMA Oncol. 2021 Nov 1;7(11):1678-1685. doi: 10.1001/jamaoncol.2021.3971.
4
Patient's perspectives of living with a precancerous condition: Monoclonal gammopathy of undetermined significance (MGUS).患者对癌前状态的看法：意义未明的单克隆丙种球蛋白血症（MGUS）。
Eur J Oncol Nurs. 2021 Apr;51:101901. doi: 10.1016/j.ejon.2021.101901. Epub 2021 Jan 17.
5
Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.随机 Lenalidomide 对照观察冒烟型多发性骨髓瘤。
J Clin Oncol. 2020 Apr 10;38(11):1126-1137. doi: 10.1200/JCO.19.01740. Epub 2019 Oct 25.
6
A survey of risk tolerance to multiple sclerosis therapies.多发性硬化症治疗风险承受度调查。
Neurology. 2019 Apr 2;92(14):e1634-e1642. doi: 10.1212/WNL.0000000000007245. Epub 2019 Mar 13.
7
Long-Term Follow-up of Monoclonal Gammopathy of Undetermined Significance.意义未明的单克隆丙种球蛋白病的长期随访
N Engl J Med. 2018 Jan 18;378(3):241-249. doi: 10.1056/NEJMoa1709974.
8
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.来那度胺扩展疗程的卡非佐米-来那度胺-地塞米松治疗冒烟型或新诊断多发性骨髓瘤患者。
JAMA Oncol. 2015 Sep;1(6):746-54. doi: 10.1001/jamaoncol.2015.2010.
9
How I treat smoldering multiple myeloma.我如何治疗冒烟型多发性骨髓瘤。
Blood. 2014 Nov 27;124(23):3380-8. doi: 10.1182/blood-2014-08-551549. Epub 2014 Oct 8.
10
Why is breast cancer chemoprevention such a hard sell?为什么乳腺癌化学预防如此难以被接受？
J Natl Cancer Inst. 2014 May 9;106(5):dju139. doi: 10.1093/jnci/dju139.
Zotero 插件